Pipeline
Carna has leveraged its expertise in kinase biology to establish an innovative product pipeline focused on cancer and immune disorders. We achieve success by coupling our deep understanding of cell signaling with our extensive drug discovery expertise to generate therapeutics that inhibit kinases and provide new treatment options for patients with high unmet medical needs.
Science
Technology
Carna has developed a robust screening engine that makes it possible to identify new generation of kinase inhibitor drugs to treat patients afflicted with serious diseases.
Partnering
Carna is interested in partnering with pharmaceutical and biotechnology companies to develop our drug candidates. Carnaʼ s powerful kinase drug discovery engine drives our pipeline expansion and the establishment of high-value partnerships.
Our drug discovery programs begin with screening our vast lead-like compound library, followed by kinase profiling to select lead candidates and optimize chemistry to identify highly selective drug candidates.
Topics
- Carna Biosciences to present new preclinical data on monzosertib at AACR Annual Meeting
- New paper was published in Nature Communications in collaboration with Prof. Taguchi of Tohoku University.
- Carna announces acceptance of two posters on AS-1763 for presentation at ASH Annual Meeting
- Carna announced positive results from the Phase 1 MAD study of sofnobrutinib (AS-0871).
- Carna announced International Nonproprietary Name(INN) selection for AS-0871 and AS-0141.